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Recently developed genomic editing technologies have the potential to be 
powerful tools for gene therapy because 
of their ability to inactivate genes, correct 
mutated sequences, or insert intact genes. 
While the genomic editing field is advanc-
ing at an exceptionally rapid pace, there 
remain key issues regarding development 
of appropriate preclinical assays to evalu-
ate off-target effects and establish safety. In 
order to begin a dialogue on these issues, 
the National Institutes of Health (NIH) 
Office of Science Policy, in collaboration 
with several NIH-funded investigators 
and the NIH Recombinant DNA Advisory 
Committee, organized a workshop on 10 
June 2014, in Bethesda, Maryland, to pro-
vide a forum to educate the scientific and 
oversight communities and the public on 
different genome editing technologies, 
clinical experiences to date, and the pre-
clinical assays being developed to examine 
the precision of these tools and their suit-
ability for clinical application.
Targeted genome modification by de-
signer nucleases is an emerging technol-
ogy that can be used to investigate gene 
function and could also be used to treat 
genetic or acquired diseases. A wide range 
of genome alterations has been achieved 
by these nucleases, including localized 
mutagenesis, local and dispersed sequence 
replacements, large and small insertions 
and deletions, and even chromosomal 
translocations. The nuclease approach to 
targeted genome editing has been applied 
successfully to more than 50 different or-
ganisms, including crop plants, livestock, 
and humans.1
Recently developed genome editing 
technologies such as zinc finger nucleases 
(ZFNs), transcription activator-like effec-
tor nucleases (TALENs), meganucleases, 
and clustered regularly interspaced short 
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palindromic repeats (CRISPR) are being 
investigated as promising tools for hu-
man gene therapy. ZFNs are the first class 
of nucleases to have reached the clinic in 
phase I trials for HIV.2 One key issue that 
will have to be addressed as these technol-
ogies move into clinical trials is whether 
technology-specific preclinical evaluations 
are available that can establish safety. Al-
though these are targeted editing tools, 
their precision, and specifically the degree 
to which there are off-target actions and 
the clinical implications of such activity 
are important questions for the field.
Overview of genome editing 
technologies
The fundamental process common to all of 
these technologies is the use of nucleases to 
make site-specific double-stranded breaks 
(DSBs) in the genome. Several approaches 
to genome editing have been developed; 
this summary describes them briefly. 
ZFNs. ZFNs are the most clinically ad-
vanced nuclease platform. Each zinc-fin-
ger consists of ~30 amino acids that fold 
into a conserved ββα configuration.3 Each 
“finger” recognizes about three or four 
base pairs of DNA using at least six amino 
acids through contacts between specific 
residues in the second α-helix, also known 
as the “recognition helix” terminus. Three 
to six individual fingers can be linked to 
enable construction of arrays that recog-
nize longer sequences of 9–18 base pairs 
(bp). Of note, 18 bp of DNA sequence can 
confer specificity within 68 billion base 
pairs of DNA. Further specificity can be 
engineered by changing critical residues 
within the recognition helices. In addi-
tion, individual fingers in an array can 
potentially interact and make base-specific 
contacts into the sequences recognized by 
adjacent fingers, and optimization of bind-
ing can therefore be potentially altered by 
interactions between individual fingers. 
The nuclease domain of the zinc-finger is 
derived from the C-terminus of the FokI 
restriction endonuclease. FokI only cuts 
DNA when it dimerizes, so two sets of 
zinc-fingers are required (see Figure 1a). 
The natural enzyme generates a 5 over-
hang. However, one can engineer these en-
zymes such that within the dimer, one side 
of the nuclease domain is catalytically ac-
tive while its twin is catalytically inactive, 
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Figure 1 Nuclease site recognition features
(a) Zinc-ﬁnger nuclease dimer: recognition sites 
9–18 bp × 2. (b) TAL effector nuclease (TALEN): 
recognition sites 12–20 bp × 2, spacer 12–20 bp. 
(c) RNA-guided endonuclease CRISPR/Cas9. 
Courtesy of Matthew Porteus
ing up to six mismatches and/or bulges. 
Similar to ZFNs, it is possible to make a 
nick rather than a break with the CRISPR/
Cas9 system. However, unlike the ZFNs 
and TALENs, the double-strand cut made 
by CRISPR/Cas9 leaves a blunt end.
 
Homing endonucleases (meganucle-
ases). These are natural proteins called 
endodeoxyribonucleases that recognize 
long (>12 bp) DNA sequences with high 
specificity. Described as genetic parasites, 
they target the recognition site in an al-
lele, make a break in that allele, and target 
the transfer of their own protein-coding 
sequence into that allele by homologous 
recombination. They generate a DSB with 
a four-base 3 overhang, which is proposed 
to be a natural substrate for the homolo-
gous recombination machinery. Initial 
genome editing manipulations were done 
using the I-CreI and the I-SceI endonucle-
ases. Engineering these nucleases is dif-
ficult primarily because both recognition 
and enzymatic activity are intertwined 
within the protein, often making it difficult 
to alter one without having an effect on the 
other. However, these nucleases are small 
and can be easily contained in commonly 
used vectors. In sum, they offer potentially 
high specificity, but barriers to their engi-
neering are high.9
Impact of double-stranded breaks
The mechanism unifying each of these 
technologies is the ability to make targeted 
DSBs in genomic DNA. The outcome of 
targeted cleavage depends on cellular re-
pair pathways of DSBs, which are poten-
tially lethal to the cell unless they are re-
paired quickly. The principal mechanisms 
of repair are nonhomologous end joining 
(NHEJ) and homology-dependent repair 
(HDR) (see Figure 2). NHEJ often results 
in sequence changes at the cut site, most 
commonly variable-length insertions or 
which will generate a single-stranded nick 
rather than a DSB.
 
TALENS. TALENs are similar in architec-
ture to ZFNs except that they use a differ-
ent DNA-binding domain. They consist of 
arrays of single protein modules that each 
recognize a single DNA base pair and that 
are derived from transcription activator-
like effectors (TALEs), factors encoded by 
plant pathogenic bacteria4 (see Figure 1b). 
Each of these modules is about 34 amino 
acids long, and they are nearly identical 
except for the identities of amino acids at 
positions 12 and 13, which together are 
known as the “repeat variable di-residue”. 
To engineer DNA-binding domains with 
novel DNA-binding specificities, indi-
vidual TALE repeats are assembled into 
an array that is designed to recognize the 
target DNA sequence. Although the sin-
gle-nucleotide specificity of TALE repeats 
potentially offers greater design flexibility 
than do zinc-fingers, their highly repeti-
tive nature presents technical challenges in 
assembling DNA-encoding arrays of these 
domains. Different strategies have been 
developed to facilitate rapid assembly of 
DNA-encoding TALE repeats, includ-
ing the “Golden Gate” assembly method5 
and a system called FLASH.6 TALE repeat 
arrays that recognize 13–20 bp can be 
 constructed. The nuclease domain used 
in TALENs is also from FokI; however, in 
contrast to ZFNs and for reasons that are 
not yet understood, TALENs cannot be 




tein 9. CRISPR/Cas9 is distinct from 
the previous engineered endonucleases 
in that it uses an RNA-guided system to 
perform genome editing. This platform, 
derived from a bacterial innate immune 
system, was described relatively recently, 
but progress on its development has been 
rapid. It has captured considerable atten-
tion due to the relative ease of engineering 
its RNA-based targeting component. In 
bacteria, type II CRISPR systems process 
foreign sequences from invading phages 
or plasmids into small segments that are 
then introduced into the CRISPR array, 
which contains the regularly interspaced 
palindromic repeats. These snippets of for-
eign DNA become templates for CRISPR 
RNA (crRNA), which now contains a vari-
able sequence from the invading DNA. 
This crRNA then hybridizes with a trans-
activating RNA (tracrRNA), and the RNAs 
form complexes with the Cas9 protein. The 
next time this foreign sequence is detected, 
it is cleaved and degraded (see Figure 1c).7
Recognition of the target DNA se-
quence is mediated between the genomic 
DNA target and by a 20-nucleotide se-
quence in the crRNA. Another feature 
of this system is that the Cas9 protein is 
directed to cleave the complementary 
target-DNA sequence if it is adjacent to a 
short sequence known as the protospacer 
adjacent motif (PAM). The PAM sequence 
commonly used from Streptococcus pyo-
genes has the sequence [N]GG, although 
[N]AG can also be used. Many bacteria 
have the Cas9 system, but not all of them 
possess the same PAM sequences, provid-
ing some additional variability. In addi-
tion, mutations in the PAM sequence will 
prevent the Cas9 protein from causing a 
break at that site. In 2012 it was shown that 
the crRNA and the tracrRNA can be com-
bined into a single RNA molecule known 
as a guide RNA (or gRNA) that can still 
engage the Cas9 protein.8 As discussed 
later, gRNAs recognize 20-bp target sites 
but can also recognize off-target sites bear-
Figure 2 Mechanisms of DNA repair after 
targeted cleavage.HDR, homology-depen-
dent repair; NHEJ, nonhomologous end 
joining. Courtesy of Dana Carroll.
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deletions, referred to as “indels,” which can 
be detected through sequencing or mis-
match cleavage assays that use enzymes 
such as CelI or T7 endonuclease I and 
more recently a new method called TIDE 
(tracking of indels by decomposition).10 
There are subtle differences among 
the NHEJ products generated by each 
of the above nucleases. Small deletions 
and insertions are common in NHEJ 
mutations, but the average deletion size 
is somewhat larger with TALENs and 
ZFNs compared to CRISPRs, and in-
sertions are somewhat more frequent 
with ZFNs.1 Rarely are insertions large 
enough that the source of the inserted 
sequences can be identified.11 Such find-
ings highlight that the mechanisms of 
DSB repair are still not completely un-
derstood.
HDR can incorporate user-provided 
sequence changes from a donor DNA. 
NHEJ dominates in almost all systems, 
but there may be ways to shift the bal-
ance toward HDR through downregu-
lation of enzymes that are involved in 
the NHEJ pathway or modulating the 
stage of the cell cycle. In addition, alter-
ing engineered nucleases to produce a 
single-stranded nick rather than a DSB 
will favor HDR, but at an overall lower 
absolute frequency of repair.12,13
If the goal is to incorporate new ge-
netic material rather than just to disrupt 
a particular sequence, the nature of the 
donor DNA will also influence the suc-
cess of the approach. With long dou-
ble-stranded donor DNAs, successful 
incorporation requires several hundred 
base pairs of homology on both sides 
of the nuclease-induced break.11,14 Short 
single-stranded donor DNAs can also 
be used, but such templates would be 
limited to applications requiring small 
changes close to the DSB, such as correc-
tion of point mutations. In some systems 
(e.g., Drosophila), sequences throughout 
the length of a long donor can be cap-
tured at the target, but in other cases 
(e.g., cultured mammalian cells) only 
sequences close to the break are rou-
tinely incorporated, although sequences 
several kilobases away can occasionally 
be incorporated.15,16 Further knowledge 
of the activities that control this feature, 
known as “conversion tract length,” is 
needed as the field moves toward gene 
insertion applications.
Improving speciﬁcity through 
design
Because genome editing is directed at spe-
cific sites, this technology offers greater 
precision compared to other approaches 
to long-term gene modification, e.g., deliv-
ery of a gene by an integrating viral vector. 
Most integrating viral vectors have a large-
ly random integration pattern. However, 
despite the elegant precision that these ed-
iting tools offer, off-target effects are likely, 
depending upon the construct and the 
length of the target site. Ideally, the inser-
tions, deletions, inversions, and transloca-
tions that may result from NHEJ or HDR 
at these off-target sites must be minimized 
before moving to the clinic.
Improving on the natural design. 
much has been learned regarding how to 
use these tools to target specific sequences, 
and the designs of these naturally occur-
ring tools are being modified to improve 
the specificity. At the workshop, Keith 
Joung reviewed his research with different 
platforms—ZFNs, TALENs, and CRISPR/
Cas9 nucleases—in which he generally has 
seen stronger binding to on-target sites 
compared with off-target sites, but there 
is still considerable activity at off-target 
sequences. Focusing on the CRISPR/Cas9 
platform, he examined the off-target ef-
fects of first-generation CRISPR/Cas9 
agents that were directed by six different 
gRNAs and demonstrated that there were 
a number of off-target sites (harboring as 
many as five mismatches relative to the on-
target site) and that the rate of mutagenesis 
at these sites could be as high as that seen 
at the on-target site.17 This analysis was 
done across different cell types, and the 
mutations sometimes fell within the cod-
ing sequences of the genome.
This finding has led to the development 
of second-generation CRISPR/Cas9 agents 
with modifications to increase specificity. 
Intuitively one might conclude that in-
creasing the length of the binding site for 
the nuclease would increase specificity, but 
Dr Joung found that for the CRISPR/Cas 
9 system, specificity can be improved by 
truncating the 5 end of the gRNA by as 
many as three nucleotides. This truncation 
generally does not impair the ability of a 
gRNA to direct on-target site cleavage but 
appears to make the gRNA/Cas9 complex 
more sensitive to mismatches and there-
fore reduces off-target site cleavage.18 This 
truncation approach does not work for all 
gRNAs but appears to work well for the 
vast majority of gRNAs tested to date. An-
other strategy is to combine the specificity 
from different platforms. For example, it is 
possible to combine the dimerization-de-
pendent FokI nuclease used in ZFNs and 
TALENs with the CRISPR/Cas9 system. 
By fusing the FokI nuclease to a catalyti-
cally inactive Cas9, one can use the gRNAs 
to direct binding but require dimeriza-
tion for cleavage.19,20 In one experiment in 
which five off-target sites were previously 
observed with the use of a specific gRNA, 
deep sequencing was used to confirm that 
the frequency of indel mutations induced 
by the dimeric CRISPR (or RNA-guided 
FokI nuclease) was not greater than back-
ground at all five off-target sites, indicat-
ing the ability of this platform to eliminate 
activity at the off-target sites of a single 
gRNA. This hybrid platform provides an 
increase in the length of the binding site by 
utilizing both gRNAs in a dimeric configu-
ration and reduction in potential off-target 
sites.19 Interestingly, in that experiment 
the authors also failed to see detectable 
evidence of off-target activity for these di-
meric RNA-guided FokI nucleases, even at 
the most closely mismatched sites in the 
genome.
Another approach being explored is 
to mutate the Cas9 protein so that it will 
only create a nick rather than a DSB. By 
then pairing two such mutated Cas9 pro-
teins with gRNAs that are offset, one can 
create DSBs while increasing the specific-
ity of cleavage and significantly reducing 
off-target breaks.21 Essentially this ap-
proach attempts to increase the specificity 
in the same way that dimerizing nucleases 
does but with the caveat that monomeric 
nickases still have the potential to induce 
mutations.19 Further research is needed to 
determine whether these strategies can be 
combined to enhance specificity further.
A recent study describes a method for 
gRNA design that significantly enhanced 
the frequency of genome editing by Cas9 
in Caenorhabditis elegans. The key inno-
vation was to design gRNAs with a GG 
 motif at the 3 end of their target-specific 
sequences. All guides designed for all 
 targets supported robust genome editing, 
both imprecise NHEJ events and precise, 
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grated transgene on neighboring gene 
expression. This can be more easily ac-
complished in cell types that can be cloned 
such as pluripotent stem cells or T lym-
phocytes, and may not be feasible in cells 
such as neural cells or hematopoietic stem 
cells. Moreover, true GSHs would have to 
tolerate (i.e., without unintended trans-
formation) the integration of a number of 
different elements, including promoters, 
enhancers, and chromatin determinants. 
Finally, validation of the safety of integra-
tion at these safe harbors should be done in 
animals; however, there are challenges in 
developing appropriate animal models.25
Identifying and evaluating the 
impact of off-target activity
Although innovative designs and explora-
tion of safe harbors are certainly important 
strategies, any clinical development strat-
egy will have to include identification and 
evaluation of potential off-target sites. A 
complete catalog of off-target sites might 
be accomplished using whole-genome se-
quencing to look for evidence of indels and 
translocations. However, this approach 
would also be very costly, especially for 
less frequent events, and the sequencing 
itself has an error rate.26 For example, if the 
off-target cleavage occurs at a frequency of 
0.1% per genome, at least 1,000 genomes 
may have to be sequenced to capture such 
a low-frequency event, adding a significant 
cost to the analysis. Furthermore, as DSBs 
and repair can occur in cells as a result of 
culture conditions alone (even in the ab-
sence of exogenous nucleases), there is the 
challenge of distinguishing the actions of 
nucleases from naturally occurring back-
ground DNA breaks and the spontaneous 
formation of small indels. In addition, 
with ongoing deep-sequencing projects, 
it is now recognized that any individual’s 
genome can contain up to 750,000 unique 
indels.27 As a result of these limitations, 
many groups have used a focused ap-
proach to base prediction of potential 
off-target sites sequence similarity to the 
on-target site followed by experimental 
confirmation to validate those predictions. 
However, the significant disadvantage 
of such a focused approach is that it will 
potentially miss other potential off-target 
sites that could have clinical significance.
Bioinformatics tools are being de-
veloped to predict off-target sites. A 
Identifying safe harbors. An alterna-
tive strategy to achieve safe, targeted 
gene delivery and limit off-target activity 
is to identify sites in the human genome 
that are at minimal risk of causing in-
sertional oncogenesis upon integration 
of foreign DNA, while being accessible 
to a highly specific nuclease with mini-
mal off-target activity. Such “genomic 
safe harbors” may be extragenic sites 
that are remote from a gene or genomic 
regulatory sequence, or intragenic sites 
(within a gene) whose disruption is 
deemed to be tolerable. Drawing from 
human clinical trial data on integration 
sites for retroviral and lentiviral vectors, 
several researchers24,25 have proposed 
the following criteria that could consti-
tute an extragenic safe harbor for DNA 
integration: A safe harbor should be (i) 
outside a gene transcription unit; (ii) lo-
cated >50 kilobases (kb) from the 5 end 
of any gene; (iii) located >300 kb from 
cancer-related genes; (iv) located >300 
kb from any identified microRNA; and 
(v) outside ultra-conserved regions and 
long noncoding RNAs. In studies of len-
tiviral vector integrations in transduced 
induced pluripotent stem cells, analysis 
of over 5,000 integration sites revealed 
that ~17% of integrations occurred in 
safe harbors. The vectors that integrated 
into these safe harbors were able to ex-
press therapeutic levels of β-globin from 
their transgene without perturbing en-
dogenous gene expression.24 
Several candidate genomic safe-har-
bor sites (GSHs) have been explored, in-
cluding AAVS1, CCR5, and the ROSA26 
locus. Although there are clinical data 
for CCR5 knockout in T cells and other 
data showing the safety of integration 
into AAVS1 in human cultured T cells, 
these sites have not been validated as 
universal GSHs.25 In addition, it is not 
known whether the gene-rich loci of 
these sites, including some oncogenes, 
will limit their use when targeting other 
cell lines.
Of course, much remains to be learned 
about sites that are identified as being 
GSHs. Non-protein-coding sequences 
may be more prevalent than currently 
known, and some data suggest that there 
may be low levels of transcription in in-
tragenic sites. Validation of such sites will 
require measuring the effect of the inte-
template HDR events.22
Dr Scharenberg reviewed work he 
has done with Cellectis Therapeutics and 
Seattle Children’s Research Institute com-
bining a meganuclease, or homing endo-
nuclease, with a TAL array.23 The goal is to 
combine the high binding specificity of the 
TAL with the high cleavage specificity of 
the meganuclease. By fusing a site-specific 
meganuclease to a TAL array that binds 
adjacent to the meganuclease target site 
(thus tethering the meganuclease adjacent 
to its desired target site), one can increase 
cleavage activity at that target site and 
minimize off-target activity, as tethering 
will not occur at off-target sites lacking an 
adjacent sequence capable of being bound 
by the TAL array. The homing endonucle-
ase has to be engineered, but the specificity 
can be improved through the engineering 
of the TAL, which is easier.
Scharenberg and colleagues have ex-
plored this construct (called a megaTAL) 
in T cells, in which the goal is to engineer 
the T cell to express a specific chimeric an-
tigen receptor and at the same time disrupt 
the native T-cell receptor alpha (TCRα). 
This approach would allow for allogeneic 
designer T cells, currently being tested 
for a number of oncology applications, to 
function without the risk of graft-vs.-host 
disease (GVHD). The activity and speci-
ficity of the meganuclease targeting TCRα 
was assessed both with and without fusion 
to a TAL array that could bind a DNA se-
quence upstream from the cleavage site for 
the TCRα-specific meganuclease. Cleav-
age of the TCRα gene using the meganu-
clease alone was ~1.6% but was increased 
by 20-fold with the megaTAL construct. 
The megaTAL was then tested with co-
transfection of each nuclease with Trex2, 
a 3 endonuclease that can trim back the 
3 overhangs that homing endonucleases 
make, thereby markedly accentuating the 
generation of indels. Addition of Trex2 
further increased the rate of disruption, 
yielding rates of TCRα disruption consis-
tently exceeding 70%.23
This research underscores that the 
specificity of these tools could be en-
hanced further by combining them to take 
advantage of their respective specificity 
and ease of engineering. Nonetheless, an 
assessment of safety and specificity using 
preclinical assays will still be necessary, no 
matter which nuclease platform is utilized
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Drawing from work with integrating 
viral vectors, Christof von Kalle has de-
veloped an assay using integrase-defec-
tive lentiviral vectors (IDLVs) to identify 
off-target breaks. IDLVs—like any other 
extrachromosomal DNA—occasionally 
get trapped in a DSB during NHEJ re-
pair, thereby stably marking these other-
wise transient and undetectable events. 
IDLV integration sites in cells treated 
with ZFNs targeting the human genes 
CCR5 and IL2RG have been analyzed by 
linear amplification–mediated (LAM) 
PCR. A clustering of IDLV integration 
sites was detected at the ZFNs on-target 
site indicative of ZFN activity. However, 
a few other genomic positions show such 
clustering of IDLVs indicative of off-tar-
get activity at those loci. Molecular anal-
yses confirmed that off-target activity 
occurred at genomic positions bearing 
homology to the ZFNs target site. With 
the detection of ZFNs off-target bind-
ing sites, one could then measure the 
frequency of off-target cleavage at a spe-
cific off-target site by deep sequencing 
to identify the exact nucleotide positions 
within the ZFNs target sequence that tol-
erate nonspecific sequence recognition, 
thereby contributing to off-target activ-
ity. Interestingly, the presence of a highly 
homologous sequence did not reliably 
predict off-target activity, indicating that 
additional unknown cellular factors also 
influence target site recognition. Using 
a similar technique, the specificity of 
TALENs targeting the human COL7A1 
gene was analyzed. Only three off-target 
positions could be detected by the de-
scribed IDLV capture approach. Thus, 
experimental determination of the off-
target activity for each designer nucle-
ase may be required. These experiments 
represent an approach to move toward 
genome-wide determination of designer 
nuclease–associated off-target activ-
ity but also demonstrate that ZFNs and 
TALENs can modify the host genome 
with an extraordinarily high selectivity.
Although this method is promising, 
the lower limit of sensitivity remains to 
be defined and the use of a viral vec-
tor has the potential to introduce some 
bias into this analysis. The question then 
becomes whether it is important from a 
clinical perspective to capture all DSBs 
or just those that happen at a particular 
target, for others small alterations in a 
similar sequence would prevent binding, 
e.g., a thymine methylation that leads to 
a 1,000-fold diminution in affinity. The 
future for these tools may be to incor-
porate biochemical data that will allow 
for some ranking of the most likely off-
target sites. With further improvements, 
these tools will be useful to allow rank-
ing of off-target sites; however, the fre-
quency at which indels occur at these 
sites will be determined by the specific 
cell type being manipulated (because 
different cell types have different muta-
genic properties) and the duration and 
level of nuclease expression.
Unbiased analysis of genome 
breaks
In addition to identifying potential bind-
ing sites for the nucleases, it is important 
to understand whether DSBs are occurring 
and what the implications of those breaks 
are. The field refers to these approaches as 
“unbiased,” as they are attempting to mea-
sure the off-target DSBs.
Although the first step in the action 
of these nucleases is to bind to the recog-
nition sequence, the nuclease must then 
cut the DNA, and it is the DSB that is the 
key off-target activity of interest. Sev-
eral biochemical approaches are being 
developed not only to look at the poten-
tial binding sites but also to see whether 
there is actual DNA cleavage. Dr Liu and 
his colleagues examined whether there 
were actual DNA breaks by ZFNs at 
off-target sites using an in vitro method 
that combined libraries of potential off-
target binding sites and deep sequencing 
to look for evidence of actual cleavage at 
those sites.29 Another method was used 
to determine the nature of off-target se-
quences cleaved by two ZFNs (CCR5 224 
and VF2468) currently in clinical trials. 
They created a series (1012 total) of mu-
tated half-sites and determined which 
of those mutations were recognized and 
cleaved and at what frequency by the two 
functional ZFNs. Using PCR and deep 
sequencing, the authors were able to 
identify specific nucleotide changes that 
could lead to off-target cleavage by both 
ZFNs. They experimentally showed that 
many off-target sequences were present 
and identified in K562 cells grown in tis-
sue culture.29
number of web-based tools have been 
developed, such as Predicted Report of 
Genome-wide Nuclease Off-Target Sites 
(PROGNOS, http://baolab.bme.gatech.
edu/Research/BioinformaticTools/prog-
nos.html). PROGNOS can provide a re-
port of potential genome-wide nuclease 
target sites for ZFNs and TALENs. Once 
a particular target site is identified, the 
program can provide a rank list of po-
tential off-target sites. These tools are 
just being developed, and their valida-
tion will require more data on actual 
off-target sites from specific constructs. 
However, once validated they have the 
potential to offer a roadmap to search 
for off-target sites.
In evaluating the nature of off-target 
sites, the problem is determining what 
degree of similarity the sequence must 
possess to lead potentially to bind-
ing and cleavage. For example, for the 
 CRISPR/Cas9 system, the 20-bp bind-
ing sequence can tolerate mismatches 
between the gRNA and its complemen-
tary target DNA sequence resulting in 
binding and nuclease action. The degree 
to which the CRISPR/Cas9 system will 
bind to these mismatched sequences 
may depend on the number, location, 
and nature of mismatches,21 but larger 
data sets are needed to discern whether 
predictive rules can be derived. Bind-
ing might occur even if there is an ex-
tra DNA base pair (sometimes referred 
to as a DNA bulge) or an extra RNA 
nucleotide (an RNA bulge). Based on the 
analysis of how specific CRISPR  gRNAs 
could still bind with such mismatches 
together with DNA or RNA bulges, Gang 
Bao and his colleagues developed a new 
tool called CRISPR Off-target Sites with 
Mismatches, Insertions and Deletions 
(COSMID).28 This tool is now being fur-
ther validated using published data on 
CRISPR off-target sites to evaluate the 
accuracy of the predictions.
While these tools are elegant and pro-
vide useful data, they are just a starting 
point, as experimental data are needed 
to validate whether the identified targets 
are real. As noted by Frederic Bushman, 
with any target there will be a signifi-
cant number of potential binding sites, 
some favored and others less so. While 
some nonfavored sites appear to be al-
most as good a match as the  intended 
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von Kalle with the IDLVs. Southern blot 
analysis indicated that 2% of the factor IX 
alleles (2% of the haploid genomes) were 
modified by homologous recombination. 
However, qPCR detected that 40% of the 
haploid genomes had an integrated AAV 
vector, much more than those that had un-
dergone homologous recombination. This 
suggested that there may be up to 20 times 
as many off-targets as compared to on-tar-
get sites. By using deep sequencing the au-
thors were able to examine the NHEJ sites 
and determined that approximately 3% of 
the sites were on-target and the remaining 
were off-target.31 Thus, of the 40% of hap-
loid genomes with AAV vector integration, 
only 1.2% had NHEJ-integrated vectors at 
the knockin site. In addition, they exam-
ined the number of AAV integrations seen 
in cells that were transduced with an AAV 
vector expressing luciferase compared to 
the cells transduced with the ZFN-AAV 
vector and detected fewer AAV sites in 
the ZFN-AAV transduced cells, suggesting 
that the ZFN-AAV may have some cellular 
toxicity compared to the AAV-luciferase.
Another set of studies examined chro-
mosomal translocations generated with 
exposure to different nucleases, not just 
ZFNs. In the event of simultaneous on-
target and off-target breaks, these may 
re-ligate, creating the potential for translo-
cations, deletions, or inversions. Dr Bush-
man described a series of experiments 
in which cells were exposed to ZFNs, 
TALENs, or CRISPR that targeted differ-
ent genes—those encoding CCR5, VEGF, 
and β-globin. Each of these nucleases was 
shown to have the expected on-target ef-
fect. However, they also saw high levels 
of translocations in all of the nuclease-
exposed cells and fewer in controls trans-
duced with a GFP-expressing vector. It 
remains to be determined to what degree 
these translocations would have clinically 
significant effects.
To further examine the significance 
of translocations, Dr Roth has focused on 
well-known naturally occurring nucleases, 
RAG1 and RAG2, that mediate recombi-
nation of the gene segments in T cells to 
create a diverse repertoire of TCRs, known 
as V(D)J recombination. The RAG nucle-
ase has considerable specificity, cleaving 
only certain sites, known as recombination 
signal sites (RSSs).32 Rejoining of the DSB 
occurs by NHEJ. The system is not perfect, 
different sites, and (iii) a CRISPR/Cas9 
to a single target site. Different doses of 
the nucleases were used. In this experi-
ment, the higher dose of ZFNs resulted 
in a significant gamma-H2AX signal 
with a dose response, which was also ob-
served with the use of TALENs, but with 
the CRISPR/Cas9 there was no increase 
in gamma-H2AX. The CRISPR was ac-
tive at the target site, raising the question 
as to whether there is something differ-
ent about the CRISPR/Cas9 break that is 
not well understood and does not result 
in the formation of gamma-H2AX.
It is important to note that many of 
these studies have been done in cell lines 
derived from tumors. Therefore, valida-
tion will still have to be performed in cell 
lines that are the clinical target. Another 
complexity is that genetic polymor-
phisms may make it more difficult to 
predict the potential off-target effects for 
any individual in human applications. 
The ideal would be to have an assay that 
could assess the potential for off-target 
sites not only in a particular cell type 
but perhaps even in an individual’s cells 
(e.g., the GUIDE-seq approach could be 
performed in the patient’s cells). While 
this may be the ideal, it is not necessar-
ily a prerequisite for proceeding to clini-
cal studies if the cumulative evidence in 
a relevant model provides a favorable 
risk–benefit ratio.
Chromosomal rearrangements: 
will they occur and should we be 
concerned?
What are the potential effects of these off-
target breaks? Dr Bushman and David 
Roth presented their research on chro-
mosomal rearrangements, which may 
lead to more severe toxicities than those 
caused by indels. Dr Bushman described 
work by Kathy High, president and chief 
scientific officer of Spark Therapeutics, us-
ing adeno-associated virus (AAV) vectors 
to deliver ZFNs to correct factor IX in a 
hemophilia mouse model. In this experi-
ment, the ZFN nuclease was used to cleave 
the factor IX target site, and then a second 
AAV vector delivered the wild-type ex-
ons to recombine into the targeted break 
made by the ZFNs.31 The AAV provided a 
marker from which to sequence out into 
the flanking DNA to determine where the 
breaks occurred, much like the work of Dr 
frequency. It was noted that as cells are 
cultured over several days, there is al-
ways the potential for DSBs, thus some 
background level is already tolerated.
Recently, Dr Joung’s lab described 
an unbiased, sensitive, and genome-
wide approach for identifying DSBs in-
duced by CRISPR/Cas9 nucleases. This 
method, known as genome-wide unbi-
ased identification of DSBs enabled by 
sequencing (GUIDE-seq), relies on cap-
ture of short double-stranded oligode-
oxynucleotides (dsODNs) into CRISPR/
Cas9-induced DSBs in cultured human 
cells.19 Fragments of genomic DNA har-
boring the dsODN can be selectively 
amplified, sequenced, and mapped back 
to the genome to precisely identify DSBs 
to the nucleotide level. GUIDE-seq pro-
files of 10 different gRNAs show that 
the number of off-target DSBs can vary 
widely from more than 150 to none de-
tectable. This method provides the first 
genome-wide method for defining DSBs 
induced by CRISPR/Cas9 nucleases and 
should provide an important tool for 
preclinical evaluation of the specificities 
of these reagents. This method seems to 
be more sensitive than the prior viral 
based methods of capturing off-target 
DSBs, because significantly more oligo-
nucleotide can be introduced into the 
cell. Since this method is sensitive and 
does not require any specialized exper-
tise in viral production—although it 
does demand significant bioinformatic 
expertise to sort out true off-target 
DSBs from noise—it is likely to become 
an important approach to assessing the 
 specificity of any given nuclease or its 
variants.
Another assay that has been used to 
detect DSBs utilizes the gamma-H2AX 
histone protein. A DSB occurring in this 
region leads to phosphorylation of H2AX 
and the formation of a gamma-H2AX 
protein. An antibody to gamma-H2AX 
is available and therefore can be used to 
quantify DSBs that result from off-target 
nuclease activity.30 It is important to note 
that there is a background level of gam-
ma-H2AX due to spontaneous DSBs. In 
K562 cells, Matthew Porteus’s lab evalu-
ated several different constructs using 
this method, bringing about the binding 
of (i) a pair of ZFNs to two different tar-
get sites, (ii) a pair of TALENs to three 
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will be reduced replication or death of 
the GFP+ cells, leading to a decline in 
the relative percentage of GFP+ cells over 
time. This provides a quantitative assess-
ment of toxicity. When this assay was 
used with selected ZFNs and TALENs, 
cell viability was inversely related to the 
dose, suggesting that nuclease concen-
tration may affect viability. To examine 
the effect of nuclease concentration on 
cell viability in primary stem cells, ZFNs 
specific for enhanced GFP (eGFP) have 
been employed in keratinocyte stem 
cells derived from an eGFP-transgenic 
neonatal mouse. ZFN on-target activity 
should eliminate GFP activity. At differ-
ent ZFN doses, high levels of on-target 
activity were seen, although as reported 
by others, cytotoxicity did increase with 
a higher dose of ZFNs.36 Under optimal 
conditions, the stem cell potential of the 
keratinocyte stem cells was not altered 
by the ZFNs.
GFP tagging can also be used to de-
tect clonal dominance, which is often, 
but not always, a precursor of genotoxic-
ity. Cells were marked with a “barcode” 
(a short nucleotide sequence that pro-
vides a unique identifier for each cell, 
either by lentiviral transduction or by 
ZFN-mediated targeted integration). By 
using deep sequencing, the clonal dy-
namics of the population can be stud-
ied over time. When the barcodes were 
introduced semi-randomly by lentiviral 
vector integration, there was evidence 
how these DSBs interact with any fragile 
sites that also exist in the cell type of in-
terest. The creation of translocations be-
tween the intended nuclease target and 
random DSBs on other chromosomes has 
also been confirmed using a LAM-PCR 
high-throughput, genome-wide, translo-
cation sequencing approach.35 These two 
methods of detecting engineered nucle-
ase-induced chromosomal translocations 
are likely to become an important new ap-
proach to assessing the safety of a genome 
editing process and raises the concern that 
targeting a site that is associated with can-
cer translocations might have an increased 
safety risk.
Functional toxicity assays: 
genotoxicity, and cytotoxicity
Identifying off-target sites and potential 
chromosomal rearrangements is critical to 
assess the safety of new constructs. For de-
veloping clinical applications, the question 
was raised as to which studies would be 
most useful for evaluating clinical toxic-
ity. Studies that may be able to identify all 
genome alterations, including those that 
have not been correlated with any cellu-
lar toxicity or clinical adverse effects, may 
provide important scientific knowledge 
but may not necessarily be most relevant 
for preclinical development. Although 
these basic science studies may be at the 
extreme edge of sensitivity, functional 
studies are needed to validate potential 
toxicity for preclinical development.
Dr Cathomen noted that concep-
tually for a given concentration of a 
nuclease, you will have on-target and 
off-target activity. The ideal concentra-
tion will be one in which you have high 
on-target activity but low off-target ac-
tivity (Figure 3, bottom). If a nuclease 
has low specificity, then the two curves 
are closer to one another and the abil-
ity to reach an effective dose without 
toxicity is limited (Figure 3, top). There 
are two main toxicity concerns specific 
to genome editing technologies: cyto-
toxicity and genotoxicity. A number of 
approaches are being developed to mea-
sure cytotoxicity. In one assay, GFP+ cells 
are used to track cell viability. Cells are 
co-transfected with a GFP expression 
plasmid and a nuclease expression plas-
mid (not all cells are transfected). If the 
nuclease activity results in toxicity, there 
and occasionally an authentic cleavage site 
is joined to closely related off-target sites, 
known as cryptic RSSs. More recently, 
NEHJ has been detected between two off-
target events (i.e., breaks made in two dif-
ferent cryptic RSSs), resulting in leukemia.
Dr Roth described an examination of 
the chromosomal abnormalities in a mouse 
that had a mutant p53 gene, making it 
prone to tumors, but expressing wild-type 
RAG. In addition to chromosomal chang-
es that would be expected in the mutant 
p53 background, some tumors seemed to 
arise from RAG-mediated translocations, 
in that they were located near known cryp-
tic RSSs. A number of these breaks near 
these cryptic RSSs resulted in deletions 
that activated oncogenes. Two recent ar-
ticles showed that RAG nucleases could be 
the driver of leukemia through off-target 
cuts resulting in recombination and dele-
tions.33,34 The relevance of this finding to 
work with other nucleases is that even with 
a well-conserved, specific nuclease, there 
is the potential for off-target activity to 
have significant biological consequences.
Engineered nucleases with arguably 
lower specificity might likewise lead to 
unpredicted and significant genomic rear-
rangements. In order to determine wheth-
er this might occur with TALENs, Dr Roth 
used TALENs designed to correct the 
β-globin locus. Genome-wide sequencing 
revealed deletions that were of equivalent 
size to those seen in some of the RAG-in-
duced tumors. A number of translocations 
were also found in chromosome 11 where 
the hemoglobin gene is located. Although 
this was a limited analysis, the discovery 
that off-target activity by RAG can lead to 
tumors and the discovery of similar types 
of translocations with a β-globin-specific 
TALEN indicate that deletions resulting 
from off-target genome breaks may be bio-
logically significant.
In recent work, Dr Joung and col-
leagues reported that translocations can 
occur between CRISPR/Cas9-induced 
on-target and off-target DSBs identified 
by GUIDE-seq.19 Interestingly, these inves-
tigators also observed that translocations 
could occur between nuclease-induced 
DSBs and nuclease-independent DSB 
hotspots also identified by GUIDE-seq. 
This latter observation suggests that it is 
important to consider not only the breaks 
caused by exogenous nucleases but also 
Figure 3. Plots showing the relationship 
between concentration of a given nucle-
ase and on-target vs. off target activity. 
A “good” nuclease should exhibit high speciﬁc-
ity and afﬁnity for its cognate binding site such 
that the mass action equilibrium will not shift in 
favor of off-target sites with small increases of 
nuclease concentrations.  “Bad” nucleases with 
low speciﬁcity are prone to bind more off-target 
sites with small changes in nuclease concentra-
tion and thus limit the ability to reach an effec-
tive non-toxic dose. Courtesy of 
Toni Cathomen.
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is a precursor or stem cell, animal mod-
els can support cell differentiation, which 
may not be possible in vitro, and thereby 
make it possible to more rigorously as-
sess functionality. Furthermore, the cell 
expansion that occurs in vivo can amplify 
genotoxic events and allow the outgrowth 
of tumorigenic cells resulting from a very 
rare event. However, the use of animal 
models to assess DNA sequence–specific 
reagents such as nucleases can be com-
plicated by differences between the hu-
man and animal target sequences, so that 
the reagents used may not recognize the 
analogous nonhuman sequences. As one 
approach to circumvent this problem, the 
gene therapy field has adopted the use of 
immunodeficient mice that can support 
the engraftment and differentiation of 
human hematopoietic systems, and these 
have been used to assess genotoxicity of 
integrating vectors in these cell tissues.39 
Such an approach may now also be used 
to assess endonuclease-based approaches 
in hematopoietic stem cells.
Paula Cannon reviewed some key 
elements of these types of experiments. 
Because the recipient mouse strains are 
immunodeficient, if tumors do arise in 
such mice, investigators must character-
ize these tumors and evaluate whether 
they are of human origin. If tumors are 
of human origin, then it will be neces-
sary to further evaluate their clonality 
with respect to a nuclease modification 
signature at any of the on- or off-target 
sites. However, clonality observed in a 
nuclease-modified cell does not neces-
sarily equal causality and may instead be 
an innocent label that merely reflects the 
tumor’s clonal origin.
While the models developed for eval-
uating mutagenic potential for integrat-
ing vectors can be adopted for nucleases, 
at least for nuclease-modified hematopoi-
etic stem cells or T cells,40 an important 
caveat is that these models have not been 
able to recapitulate the clinical tumors 
seen in the human trials with integrat-
ing viral vectors. Although insertions 
near oncogenes can be documented, the 
mouse models have not demonstrated 
the vector-driven leukemia seen in some 
subjects. The lack of toxicity in animal 
models will be an important safety check, 
as one would not want to proceed in the 
face of animal toxicity. However, the chal-
They further examined the effect on the 
cell cycle. Extensive cleavage at off-target 
sites would probably result in arrest of the 
cell cycle until the DSBs are repaired. Us-
ing HeLa FUCCI cells that express fluo-
rescently tagged cell cycle indicators, they 
again compared the ZFNs to the TALENs. 
Compared with control, the TALENs did 
not affect the cell cycle while the ZFNs did 
lead to more cells blocked at the G2 stage; 
after 3 days, more apoptosis was observed 
in those cells where the cycling was dis-
rupted.
What can be concluded about these 
results, especially in light of at least 
one ZFN against CCR5 moving into 
the clinic successfully with no evidence 
of clinical toxicity and several years of 
follow-up? Dr Cathomen noted that 
these results cannot be interpreted as 
ZFNs being generally less specific than 
TALENs. Rather, it will be important to 
carefully evaluate the genotoxic poten-
tial of every designer nuclease intended 
to enter clinical trials. Dr Porteus noted 
that these assays raise interesting ques-
tions, but there is no evidence that they 
have predictive power for clinical out-
comes. The majority of these assays have 
been done in cell lines using delivery 
strategies and/or doses that would not be 
used in clinical applications. Dr Catho-
men added that the other assays being 
used to assess genotoxicity—karyotype 
analysis and array-comparative genomic 
hybridization—are relatively insensitive. 
They may best serve as screening and 
comparison tools between platforms or 
as refinements to current platforms. If 
they are to be adapted to provide data 
regarding functional toxicity for clinical 
applications, they will have to be con-
ducted in the cell types of interest, with 
the nuclease delivered as it would be in 
a clinical trial.
The role of animal models
Although in vitro models are important 
to guide development of new approaches, 
animal models have always been used to 
more definitively explore toxicity. In the 
context of these agents, animal models po-
tentially allow for assessment of the viabil-
ity and functionality of the modified cells 
in an environment in which they will com-
pete with unmodified cells. In addition, 
for applications where the engineered cell 
of spontaneous clonal changes in the 
population but none that could be re-
producibly attributed to the lentiviral 
insertion. In contrast, the population of 
cells marked by ZFN-mediated recom-
bination at a single safe harbor showed 
greater clonal skewing, with the clonal 
dominance occurring reproducibly from 
the same clones.37 It is unclear why the 
integration of the ZFNs led to additional 
clonal growth, but the use of K562 cells 
and high doses of ZFNs may have affect-
ed these results. Furthermore, although 
this assay suggests that changes in clonal 
dynamics induced by engineered nucle-
ases can be detected, the clinical rel-
evance has not been validated.
Dr Cathomen’s group examined the 
ratio of on-target to off-target events us-
ing ZFNs and TALENs specific for CCR5 
and AAVS1. When assaying the geno-
toxicity of ZFN and TALEN pairs target-
ing CCR5, they initially focused on the 
known primary off-target site, CCR2. 
Overexpression of a highly specific 
TALEN pair did not result in detectable 
chromosomal rearrangements; however, 
these were detected following use of the 
CCR5-specific ZFN. The ratio of CCR5/
CCR2 specificity for the different nucle-
ases was determined. The CCR5-specific 
TALENs had a specificity ratio of either 
130:1 or 7:1, depending upon the target 
sequence, whereas for the CCR5-specific 
ZFNs, it was 3:1. This difference in spec-
ificity paralleled the detection of large 
chromosomal deletions or inversions in 
the area of the CCR5/CCR2 loci, where 
a highly specific TALEN pair did not in-
duce chromosomal rearrangements, but 
CCR5-specific ZFNs and the TALEN 
pair that had the lower ratio of specifici-
ty demonstrated high off-target effects.38 
Using the bioinformatics tools described 
above (PROGNOS), they found that the 
predicted ratio of on-target to off-target 
sites for the ZFN pairs targeting CCR5 
and AAVS1 was about 1:2, and the ratio 
for the CCR5-specific TALENs was 60:1; 
and for the TALENs targeting AAVS1 the 
ratio was 27:1. These constructs were then 
tested at high doses in HEK293 cells, high-
er than would be done for physiological 
dosing. About 80% of the cells transfected 
with TALENs expression vectors survived 
compared with about half of cells trans-
fected with the ZFN-encoding plasmids.38 
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target. Immunostaining for DSBs was also 
done using p53-binding protein1 (53BP1), 
which is recruited to sites of DSBs early 
in their repair and is required for NHEJ.43 
Importantly, there is a background rate of 
positive sites reflecting the physiological in-
cidence of DSBs. Transduction of the cells 
using the adenoviral vector carrying the 
CCR5-specific ZFNs resulted in an increase 
in DSBs of 1.4–1.6% compared with 4.1% in 
the presence of a chemotherapy agent eto-
poside. Because CCR2 is in close proximity 
to CCR5, it was not possible to visualize two 
independent 53BP1 foci by staining.43
Following these molecular assays, a se-
ries of in vitro and in vivo assays were con-
ducted to establish safety and in particular, 
the absence of oncogenic potential. In vitro 
oncogenicity assays were based on the expe-
rience in previous gene therapy T-cell prod-
uct characterizations. In addition, because 
the cancer chemotherapy cytotoxic agents 
have the greatest genotoxic and carcinogen-
ic potential, standard in vitro studies for pre-
clinical evaluations of these types of drugs 
were also used. The ability of a primary T 
cell to grow without cytokines and cell sig-
naling is a feature of carcinogenic transfor-
mation. Culturing of  SB-728-T cells without 
cytokine support was performed for weeks 
and demonstrated that normal cell death 
occurred. The classic biological cell trans-
formation assay is anchorage-independent 
growth of fibroblasts and is a stringent test 
of carcinogenesis. These fibroblasts are also 
amenable to gene transfer by adenovirus, so 
delivery of the ZFNs into these cells can be 
achieved. The US Food and Drug Admin-
istration (FDA) asked Sangamo to use as 
high a multiplicity of infection as possible 
for these tests. Other tests evaluated but not 
chosen to evaluate for oncogenicity were 
the Ames test, Mouse micronucleus test, 
and mouse lymphoma TK gene mutation 
assay.
SB-728-T in vivo safety studies relied on 
the fact that human T cells could be main-
tained in immunodeficient NOG mice. 
After discussion with the FDA, Sangamo 
tested a full human dose of modified T cells 
(using T cells from three different donors), 
allowed the modified human T cells to live 
and expand for months in the NOG model, 
and tested this against T cells modified us-
ing a maximal multiplicity of infection in 
order to recreate a “worst case” scenario. 
It took some time to develop a model with 
vector into mature T cells. To determine the 
impact of this nuclease on the T cells, San-
gamo undertook a series of assays in which 
the phenotype and the growth kinetics of 
the modified T cells were compared to those 
of unmodified T cells. Cytokine release was 
also determined to be the same in modified 
versus unmodified T cells, and there was no 
skewing of the diversity of the TCR vari-
able domain. Finally, it was determined that 
the CCR5-modified T cells are stable in the 
population in the absence of HIV infection, 
and HIV infection leads to enrichment of 
the CCR5-modified T cells.
In addition to these experiments, it was 
important to analyze the fidelity of the ge-
nome editing. The first step was to focus 
on molecular assays that could identify pri-
mary off-target action, i.e., DSBs. Although 
bioinformatics tools were a starting point, 
an unbiased approach was also needed. 
One can deep-sequence sites that are the 
closest matches to the consensus site for the 
ZFNs binding sites, as identified using bio-
informatics tools. This deep sequencing can 
detect events as rare as 1:10,000 alleles but 
is limited by the fact that the initial screen 
is identifying a relatively small number of 
sites per sequence. One can also use im-
munostaining for DSBs, which is unbiased 
but again limited to about 100 individual 
nuclei per conditional time point. As dis-
cussed above, genome-wide assessment of 
ZFNs-induced DSBs using IDLV capture 
and nonrestrictive LAM-PCR is another 
approach, but it is limited by the sensitivity 
of IDLV capture at rare DSBs. Nonrestric-
tive LAM-PCR does not utilize restriction 
enzymes to cleave the genomic DNA, which 
may reduce sensitivity to detect some sites, 
but its use of sonication shearing should 
increase sensitivity. Finally, karyotyping of 
cells can reveal genomic rearrangement, but 
the number of cells analyzed per sample is 
low. In addition, nonclonal rearrangements 
are often present in untreated cells, making 
it important to also determine the back-
ground incidence.
In the development of the CCR5 prod-
uct, Sangamo identified 15 potential off-
target sites and then used deep sequencing 
(454 sequencing) to look for DSBs at the 
identified sites. This allowed for identifi-
cation of one off-target site in 1:20,000 al-
leles, and the identification of one other 
site, CCR2, that had about a 4% frequency 
of DSBs compared with ~35% at the CCR5 
lenges in developing appropriate, efficient 
animal models to evaluate genotoxicity 
and in particular oncogenicity for inte-
grating vectors have been documented,41 
and similar challenges may arise as these 
models are used to evaluate genome edit-
ing technologies.
Bringing it all together: moving 
into the clinic
At the time of this meeting, only ZFNs have 
advanced to clinical trials. The first success-
ful clinical application for genome editing 
has been seen with a ZFN targeting CCR5, 
a receptor expressed on T cells that allows 
HIV to enter.2 Phil Gregory and Dale Ando, 
Sangamo BioSciences, reviewed their path 
to the clinic. Development of this product 
began in 2003 when many of the assays 
reviewed during the meeting were not yet 
available. Dr Gregory noted that the path 
taken for these products is in some ways the 
same for any pharmaceutical development, 
including generating therapeutic reagents 
that are maximized for potency/specificity 
and working within established regulatory 
frameworks to characterize the safety of 
the product. For genome editing, an addi-
tional challenge that is unique to this class 
of “drugs” is the need to define specificity in 
addition to classical toxicology assessment. 
Also, identification of off-target sites is com-
plicated by the lack of a clear footprint in the 
genome, unlike those of integrating vectors, 
which could be easily detected.
One of the first steps with this platform 
development was to maximize the speci-
ficity of the ZFNs. As discussed above, the 
ZFN modules each recognize three base 
pairs. These modules can be combined so 
that the interface is highly specific. In addi-
tion, the linkers between the modules and 
the links between the Fok1 nuclease and 
the modules can be altered to maximize en-
gagement of the preferred sequence. More-
over, the Fok1 domains can be engineered 
to require heterodimer binding. Because of 
these variables, up to 105 ZFN dimers can be 
generated for a particular exon region. The 
selection of a candidate to move forward 
into the clinic required the use of bioinfor-
matics and selection technologies such as 
phage display42 to identify the product that 
is maximized for specificity and activity.
The ZFN-CCR5 used in clinical tri-
als developed by Sangamo, known as 
 SB-728-T, was delivered by an adenoviral 
Molecular Therapy  vol. 23  no. 5  may 2015 805
© The American Society of Gene & Cell Therapy meeting report
to allogeneic transplants—the standard of 
care—then the risk of an off-target event 
that might have an unforeseen clinical out-
come should be weighed against the known 
20–30% risk of GVHD and a 5–10% risk of 
death.
Another safety feature may be the 
choice of initial cells to target with these 
tools. Sangamo Biosciences conducted their 
initial ZFNs clinical trial in a terminally 
differentiated T cell. New trials are explor-
ing the same construct in stem cells. If one 
looks at the experience in gene therapy, the 
same type of retroviral vector that caused 
leukemia when used in hematopoietic stem 
cells in trials for X-linked severe combined 
immunodeficiency, chronic granulomatous 
disease, and Wiskott-Aldrich syndrome, 
has not led to leukemia in other protocols 
that have used terminally differentiated T 
cells, even though the ability to transform 
T cells in a preclinical setting has been 
demonstrated.44 Monitoring the behavior 
of these nucleases in differentiated cells, 
and looking for normal activity and dif-
ferentiation, provides some data that these 
nucleases are not disrupting cellular activity 
through action at other loci. However, the 
counterargument to this is that safety in the 
differentiated cell does not guarantee safety 
in the stem cell.
Several new investigators in this field 
come from the gene therapy field, and in 
particular the area that uses integrating 
vectors to accomplish long-term gene cor-
rection. The genome editing field draws on 
the experience of those studying integrat-
ing vectors. However, there are limits in the 
ability to extrapolate from the experience 
with integrating vectors and their assays. 
For example, in the field of gene therapy, 
one group looked at integration sites for 
the same vector in T cells vs. stem cells and 
found different integration patterns. How-
ever, when the ZFN for CCR5 was exam-
ined in T cells and hematopoietic stem cells, 
there were no differences in the off-target 
sites for the CCR5 in T or CD34+ cells, un-
derscoring that while vector integration is 
largely random, the action of these products 
is more directed, including any off-target 
events.
It is as yet unclear if the preclinical path-
way for these technologies will differ de-
pending upon whether the goal is gene dis-
ruption, correction, or insertion. Certainly 
there would be additional challenges when 
activity.
One question is whether it is necessary 
to detect every potential indel. Is there a 
level below which one could be confident 
that the frequency would not lead to a clini-
cally significant lesion? Does a focus on the 
most frequent off-target sites, perhaps with 
a particular focus on translocations, suffi-
ciently help ensure safety? It is unlikely that 
the nature of the repair product can reliably 
predict function, as not all deletions are 
benign; moreover, although translocations 
are frequent in tumors, there may be many 
translocations that do not lead to transfor-
mation events. Therefore, it may not be nec-
essary to identify all off-target activity but 
rather to develop assays that reliably iden-
tify transformation of cells. In addition, as 
the specificity of these nucleases improves, 
the frequency of off-target DSBs may de-
crease to a level that may reasonably allow 
the analyses to focus on the most prevalent 
of the off-target sites.
Assay development may be an essential 
milestone in the development pathway be-
fore a commitment is made to a particular 
engineered nuclease. One could begin with 
using biochemistry/bioinformatics/molec-
ular assays to evaluate candidate nucleases 
and their potential for off-target and cellu-
lar toxicity. These results may then be used 
to optimize the products. Once the optimal 
specificity has been engineered and any off-
target sites identified, there will be a need 
for more classical measurements of toxicity 
and genotoxicity, both in vitro and in vivo. 
Importantly, these assays may have to be 
adapted to focus not only on the nuclease 
but also on the proposed method of vector 
transduction and the cell context.
On a more practical level, this is a rapid-
ly developing field, with new ways to assess 
the activity of these constructs emerging at 
an equally fast pace. Ultimately decisions 
will need to be made regarding which assays 
are scientifically valid and which are needed 
to satisfy the legal-regulatory framework. 
There are a number of assays that may 
provide some data on safety, but each has 
limitations in terms of sensitivity. When as-
sessing the impact of rare events, the ques-
tion is often how many negative readouts 
are needed to provide confidence that one 
can proceed into the clinic. This risk–ben-
efit calculus must also take into account 
the proposed disease target. For example, 
if these approaches will offer alternatives 
human T-cell xeno-GVHD, defining that 2 
months was a maximal time for prolifera-
tion of cells before animals died of GVHD, 
and defining a dose and donors that gave re-
liable GVHD in the NOG mice. Three stud-
ies were performed (one for each donor), 
with a duration of 2 months, and then ani-
mals were euthanized; all organs were eval-
uated by histology for neoplasms, immu-
nostaining to detect human cells, and PCR 
for detection of ZFNs CCR5 modification 
at on-target and off-target sites. Histology 
was consistent with GVHD in liver, lung, 
gut, and spleen, showing intense inflamma-
tory infiltration. Human DNA was present 
in all animals, and there was equivalent en-
graftment of modified and control cells. No 
CCR5-related CD4 T-cell neoplasms were 
found.
These studies led to the first genome ed-
iting phase I trial conducted by Pablo Tebas 
and Carl June at the University of Penn-
sylvania.2 In that study, administration of 
CCR5-modified T cells was safe, marked in-
creases in total CD4 T cells were observed, 
and the modified T cells trafficked normally 
to the gut. One subject achieved controlled 
HIV viral load below levels of detection af-
ter an antiviral treatment interruption of 12 
weeks. The ZFNs-modified T cells persisted 
at a level >50 modified CD4 T cells/μl for 
252 weeks. 
Putting it all together for future 
clinical applications
The meeting reviewed a number of assays 
that are being developed but are yet to be 
validated. The question remains how to best 
integrate these assays into the preclinical 
development strategy. A goal for the field 
may be to build assays prospectively for a 
particular outcome, defining the sensitivity 
and cutoff values in advance. It was noted 
that although the meeting proposed to fo-
cus on “establishing preclinical toxicology 
standards,” the main focus was on detecting 
and evaluating off-target effects. It was ac-
knowledged that one way to evaluate these 
technologies is using an unbiased approach 
such as whole-genome sequencing to un-
derstand where these nucleases act in the 
genome, but the cost and potentially low 
sensitivity makes this approach impracti-
cal for preclinical development. Instead, the 
goal has been to find predictive tools that 
allow for a more focused evaluation of the 
most likely off-target sites with significant 
806 www.moleculartherapy.org  vol. 23  no. 5  may 2015
© The American Society of Gene & Cell Therapymeeting report
REFERENCES
1. Carroll, D (2014). Genome engineering with targe-
table nucleases. Annu Rev Biochem 83: 409–439.
2. Tebas, P, Stein, D, Tang, WW, Frank, I, Wang, SQ, 
Lee, G et al. (2014). Gene editing of CCR5 in autolo-
gous CD4 T cells of persons infected with HIV. N Engl 
J Med 370: 901–910.
3. Gaj, T, Gersbach, CA and Barbas, CF 3rd (2013). 
ZFN, TALEN, and CRISPR/Cas-based methods for 
genome engineering. Trends Biotechnol 31: 397–405.
4. Bogdanove, AJ and Voytas, DF (2011). TAL effectors: 
customizable proteins for DNA targeting. Science 
333: 1843–1846.
5. Cermak, T, Starker, CG and Voytas, DF (2015). Ef-
ﬁcient design and assembly of custom TALENs using 
the Golden Gate platform. Methods Mol Biol 1239: 
133–159.
6. Reyon, D, Maeder, ML, Khayter, C, Tsai, SQ, Foley, 
JE, Sander, JD et al. (2013). Engineering customized 
TALE nucleases (TALENs) and TALE transcription fac-
tors by fast ligation-based automatable solid-phase 
high-throughput (FLASH) assembly. Curr Protoc Mol 
Biol Chapter 12: Unit 12.16.
7. Sander, JD and Joung, JK (2014). CRISPR-Cas systems 
for editing, regulating and targeting genomes. Nat 
Biotechnol 32: 347–355.
8. Jinek, M, Chylinski, K, Fonfara, I, Hauer, M, Doudna, 
JA and Charpentier, E (2012). A programmable dual-
RNA-guided DNA endonuclease in adaptive bacterial 
immunity. Science 337: 816–821.
9. Silva, G, Poirot, L, Galetto, R, Smith, J, Montoya, G, 
Duchateau, P et al. (2011). Meganucleases and other 
tools for targeted genome engineering: perspectives 
and challenges for gene therapy. Curr Gene Ther 11: 
11–27.
10. Brinkman, EK, Chen, T, Amendola, M and van 
Steensel, B (2014). Easy quantitative assessment of 
genome editing by sequence trace decomposition. 
Nucleic Acids Res 42: e168.
11. Hendel, A, Kildebeck, EJ, Fine, EJ, Clark, JT, Punjya, N, 
Sebastiano, V et al. (2014). Quantifying genome-
editing outcomes at endogenous loci with SMRT 
sequencing. Cell Rep 7: 293–305.
12. Gilbert, LA, Larson, MH, Morsut, L, Liu, Z, Brar, GA, 
Torres, SE et al. (2013). CRISPR-mediated modular 
RNA-guided regulation of transcription in eukaryotes. 
Cell 154: 442–451.
13. Wang, J, Friedman, G, Doyon, Y, Wang, NS, Li, CJ, 
Miller, JC et al. (2012). Targeted gene addition to 
a predetermined site in the human genome using 
a ZFN-based nicking enzyme. Genome Res 22: 
1316–1326.
14. Beumer, KJ and Carroll, D (2014). Targeted genome 
engineering techniques in Drosophila. Methods 68: 
29–37.
15. Elliott, B, Richardson, C, Winderbaum, J, Nickoloff, 
JA and Jasin, M (1998). Gene conversion tracts from 
double-strand break repair in mammalian cells. Mol 
Cell Biol 18: 93–101.
16. Stark, JM and Jasin, M (2003). Extensive loss of het-
erozygosity is suppressed during homologous repair 
of chromosomal breaks. Mol Cell Biol 23: 733–743.
17. Fu, Y, Foden, JA, Khayter, C, Maeder, ML, Reyon, D, 
Joung, JK et al. (2013). High-frequency off-target 
mutagenesis induced by CRISPR-Cas nucleases in 
human cells. Nat Biotechnol 31: 822–826.
18. Fu, Y, Reyon, D and Joung, JK (2014). Targeted 
genome editing in human cells using CRISPR/Cas 
nucleases and truncated guide RNAs. Methods Enzy-
mol 546: 21–45.
19. Tsai, SQ, Zheng, Z, Nguyen, NT, Liebers, M, Topkar, 
VV, Thapar, V et al. (2014). GUIDE-seq enables 
genome-wide proﬁling of off-target cleavage by 
CRISPR-Cas nucleases. Nat Biotechnol 33: 187–197.
20. Guilinger, JP, Thompson, DB and Liu, DR (2014). 
Fusion of catalytically inactive Cas9 to FokI nuclease 
improves the speciﬁcity of genome modiﬁcation. Nat 
Biotechnol 32: 577–582.
21. Ran, FA, Hsu, PD, Lin, CY, Gootenberg, JS, Koner-
mann, S, Trevino, AE et al. (2013). Double nicking 
by RNA-guided CRISPR Cas9 for enhanced genome 
editing speciﬁcity. Cell 154: 1380–1389.
22. Farboud, B and Meyer, BJ (2015). Dramatic enhance-
ment of genome editing by CRISPR/Cas9 through 
improved guide RNA design. Genetics, e-pub ahead 
of print 18 February 2015.
23. Boissel, S, Jarjour, J, Astrakhan, A, Adey, A, Gouble, A, 
Duchateau, P et al. (2014). megaTALs: a rare-cleaving 
nuclease architecture for therapeutic genome engi-
neering. Nucleic Acids Res 42: 2591–2601.
moving beyond gene disruption—which 
has been the focus of clinical applications 
to date—to gene replacement. Gene cor-
rection faces the challenge that DSBs could 
also be repaired by NHEJ; therefore, if this 
approach is to be safe, site selection must be 
such that disruption would not lead to ad-
verse effects.
It remains to be determined whether 
genome editing to achieve gene addition 
will be safer compared to gene therapy 
approaches using randomly integrating 
vectors. Although there is considerable 
experience with gene delivery via integrat-
ing vectors, efficient gene delivery into a 
predetermined site using nuclease technol-
ogy and homologous recombination is still 
being developed. The therapy that will pre-
vail may not be the most elegant but must 
be proven to be safe, effective, and easy to 
implement at multiple manufacturing sites, 
and provide an advantage over treatments 
or approaches that currently exist. Targeting 
expression from a specific site, even if well 
characterized, may not provide more effica-
cious levels of expression than the expres-
sion from multiple random sites achieved 
with integrating vectors.
There remains a gap in our current un-
derstanding of certain aspects of these tech-
nologies that may be important in evaluat-
ing clinical applications. For example, in 
developing new TALENs and  CRISPRs, 
when a reagent does not work at the ex-
pected target, it has been relatively easy to 
adjust the sequence and manufacture a new 
one rather than exploring why the agent did 
not work.
An ultimate goal would be to establish 
regulatory pathways requiring well-under-
stood, standard assays, so that one could 
sequence the genome of a patient or infant, 
identify a target, make sequence-specific 
reagents, and (because of the similarity to 
the approaches that have been previously 
successful in the clinic) develop a person-
alized reagent that is ready for clinical use 
in 2–3 months. The development of such a 
well-defined validated process may be the 
ultimate path for precision medicine.
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